Prevention of complications in type 2 diabetes mellitus
Bruce H.R. Wolffenbuttel, Józef DrzewoskiMed Sci Monit 1999; 5(5): RA1013-1019 :: ID: 503445
Abstract
It is expected that the number of patients suffering from diabetes mellitus will increase in the near future. The high rate of microvascular and macrovascular complications developing in these patients will place an even higher burden on our health care systems. Several pathophysiological factors are involved in the development of complications, among which the hyperglycaemia per se, the consequent formation of advanced glycation end products and the intracellular accumulation of sorbitol. In addition, hypertension and dyslipidaemia also play an important role, especially in the development of coronary heart disease and stroke. The major therapeutic goals in type 2 diabetic patients are to optimize blood glucose control, to reduce overweight and to normalize lipid disturbances and elevated blood pressure, in order to improve the well-being of the patient and reduce the risk for the development of late diabetic complications. The UKPDS has clearly demonstrated that achievement of near-normoglycaemia - with sulfonylurea and/or insulin - can reduce the severity of microvascular complications, and that aggressive lowering of elevated blood pressure - with a beta-blocker or an ACE inhibitor - reduces both micro- and macrovascular complications. Secondary intervention studies have demonstrated the beneficial effects of treatment with beta-blockers, aspirin, and inhibitors of cholesterol synthesis, in diabetic patients after myocardial infarction or with angina pectoris. For coronary revascularisation, a preference for CABG in comparison with PTCA in diabetic patients with coronary multivessel disease was suggested. In addition, aggressive near-normalisation of blood glucose levels in the acute phase of myocardial infarction improves prognosis, and reduces 1-year mortality by 31%.
Keywords: treatment, type 2 diabetic patients, Diabetes Mellitus
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952